Cytel

Cytel is a clinical research organization and software provider whose mission is to unlock the power of data, empowering life science leaders to realize the full potential of their therapies. The company serves pharmaceutical, biotechnology, and medical device organizations across the full drug development lifecycle — from early discovery and preclinical stages through Phase I–III clinical trials, commercialization, and post-authorization activities. Cytel combines advanced analytical methods, data science expertise, and purpose-built software to help clients design better trials, deliver them efficiently, and generate the evidence needed for regulatory and commercial success.

Cytel's offerings span strategic consulting, functional service provider (FSP) models, project-based analytical solutions, and a suite of proprietary software products. The company also operates through specialized subsidiaries and partnerships, including stève consultants, which focuses on real-world evidence and health technology assessments.

Drug Development Cycle Solutions

• Discovery and Preclinical: Innovative analytics and insights supporting drug development from inception through preclinical stages, including toxicology solutions, chemistry, manufacturing and controls (CMC), and model-informed drug development (MIDD).
• Phase I–III Clinical Trials: Data-driven methods and strategies tailored to navigate complex trial phases efficiently, covering clinical pharmacology, drug metabolism and pharmacokinetics (DMPK), adaptive trial designs, and complex and innovative trial design (CITD).
• Commercialization: Advanced analytical methods and data science to maximize market potential and optimize commercial strategies, including market access, regulatory strategy, and health economics and outcomes research (HEOR).
• Real-World Evidence Solutions: Harnessing real-world data (RWD) and real-world evidence (RWE) to gather insights, shape future drug development cycles, and support regulatory compliance, including post-authorization safety studies and synthetic and external controls.

Strategic Data Science and Analytical Methods

• Clinical Trial Design: Crafting optimal trial designs using advanced analytical methods to enhance efficiency and increase the probability of success, including adaptive trial designs and complex and innovative trial design approaches.
• Trial Delivery: Transforming trial designs into actionable strategies through a data-driven approach, encompassing end-to-end biometrics, data management, early and late phase solutions, the Axio® Data Monitoring Committee service, safety and regulatory compliance, and medical writing.
• Advanced Analytics: Delivering actionable insights to drive informed decisions and optimize clinical trial outcomes, including model-informed drug development, data strategy, and clinical development strategy and planning.
• Specialty Areas: Tailored analytics solutions for specialized or niche projects, covering rare diseases, oncology, decentralized trials, pediatrics, and post-authorization safety studies.

Delivery Models

• Strategic Consulting: Enhancing clinical trial design with adaptive trial models and comprehensive regulatory guidance to ensure innovative, compliant, and successful trial outcomes.
• Beyond Functional Service Provider (Analytics on Demand): Flexible strategic partnerships providing adaptive and innovative solutions that transcend traditional FSP models, including staff augmentation, strategic capacity management, hybrid FSP models, and functional service provider arrangements.
• Project-Based Analytical Solutions: Specialized expertise and end-to-end biometrics for unique projects, ensuring timely completion and exceptional results, including data submission support and outsourcing per project.

Software Solutions

• Trial Design Software (East Horizon™ Platform): A software platform enabling precise trial design and simulation, utilizing adaptive and Bayesian tools to optimize protocols and accelerate drug development with confidence and efficiency.
• Trial Implementation and Decision Support Software: An integrated software package that streamlines trial implementation with intuitive solutions for protocol development, randomization, and patient management, optimizing operational efficiency and ensuring study success.
• LiveSLR® Software for Systematic Literature Reviews: A dedicated software solution supporting systematic literature reviews, accessible via a dedicated login portal for clients.
• Real-World Data Software: Purpose-built tools supporting real-world data analysis and evidence generation.

Health Economics, Market Access, and Real-World Evidence

• Health Economics and Outcomes Research (HEOR): Analytical support for demonstrating the value of therapies to payers and regulators.
• Market Access: Strategies and analytics to support successful product launches and reimbursement decisions.
• Health and Technology Assessments: Evidence generation and analytical support for HTA submissions, delivered in part through stève consultants.
• Regulatory Strategy: Guidance and analytical support to navigate complex regulatory environments across development and post-authorization phases.
• Synthetic and External Controls: Advanced methodologies for generating control arms from real-world or historical data, particularly relevant for rare disease and oncology programs.

With a comprehensive portfolio spanning the entire drug development continuum — from preclinical analytics and adaptive clinical trial design to real-world evidence, HEOR, and proprietary software — Cytel positions itself as a full-spectrum partner for life science organizations seeking to accelerate development timelines, improve trial success rates, and bring effective therapies to patients more efficiently.